



Life's end Benefits of cannabidiol (CBD) and tetrahydrocannabinol (THC)

Providing hope for a potentially safe and effective **treatment** at the **end of life** for people with **agitation** related to **dementia**.

What is the LIBBY Study?

The **Life's-end Benefits of cannabidiol and tetrahydrocannabinol (LIBBY)** Study is the first of its kind to examine possible benefits of Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) as a safe treatment option for hospice-eligible people with agitation and any type of dementia.

What is involved?

Over 12 weeks, participants will receive a THC/CBD combination or placebo in the form of an oral, digestible oil.

There will be in-person and telephone appointments for the participant and study partner. Depending on where participants reside, in-person visits may take place at home or at a facility.

Financial reimbursement for each completed study visit may be available for study participants and their study partners. Please contact your nearest study site for details.

Who is eligible?

- Adults, age 40 or older
- In hospice or hospice eligible
- Experiencing agitation
- Dementia diagnosis
- Have a study/care partner

Contact your nearest study site

UK Sanders-Brown Center on Aging
859-323-1331

Visit LibbyStudy.org or call 1-800-LIBBY-11

Scan here to learn more



Funded by the National Institute on Aging (NIA) of the National Institutes of Health (NIH). Led by Alzheimer's disease research experts at the NIH-funded Alzheimer's Clinical Trials Consortium (ACTC).